Fourth, new clinical variants are constantly identified and have limited data in bioactivity databases compared to established variants . This does not mean that these variants are less important, and thus more appropriate channels for variant tracking should be consulted simultaneously to assess clinical relevance. Finally, the data and results presented here should not be restricted to bioactivity modelling for virtual screening, and thus the exploration of other modelling tasks considering protein variants is highly encouraged including (and not restricted to) selectivity modelling , drug design by fragment merging , or pharmacophore modelling .